Inputs: momentum, trendVelocity
Momentum 12/100 with trend velocity 22/100 — trend is rolling over.
Prediction result · Ensemble engineUpdated 3:55 AM
IMVTImmunovant, Inc. stock price outlook
$29.17-1.59% since prev closeBearish
Immunovant, Inc. (IMVT) is trading at $29.17, down 1.59% since the previous close and +2.68% over the past week. Price sits below its 50-day average by 15.59%, with price momentum at 12/100 and trend velocity at 22/100. Sentiment across 5 recent headlines reads net constructive at 58/100. Volatility risk is moderate (56/100) and the stock is 32% of the way up its 52-week range. The weighted factor score lands at 34/100 — a bearish signal. Research only, not investment advice.
Universal leanmarket
IMVT
Immunovant, Inc.
$29.17-1.59%
LEANSOFT mild pressure
WHY
- Immunovant, Inc. (IMVT) is trading at $29.17, down 1.59% since the previous close and +2.68% over the past week. Price sits below its 50-day average by 15.59%, with price momentum at 12/100 and trend velocity at 22/100. Sentiment across 5 recent headlines reads net constructive at 58/100. Volatility risk is moderate (56/100) and the stock is 32% of the way up its 52-week range. The weighted factor score lands at 34/100 — a bearish signal. Research only, not investment advice.
- Bear input: Momentum 12/100 with trend velocity 22/100 — trend is rolling over.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate on a reclaim of the session offer, catalyst relief, or model edge flipping bullish.
AI Signal
Bearish · Strong bearish edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
5 relevant headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment58/100
Price Momentum12/100
Trend Velocity22/100
Volatility Risk56/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
Immunovant, Inc. (IMVT) is trading at $29.17, down 1.59% since the previous close and +2.68% over the past week. Price sits below its 50-day average by 15.59%, with price momentum at 12/100 and trend velocity at 22/100. Sentiment across 5 recent headlines reads net constructive at 58/100. Volatility risk is moderate (56/100) and the stock is 32% of the way up its 52-week range. The weighted factor score lands at 34/100 — a bearish signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
31% of trees lean bearish on IMVT
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong bearish edgeBearish
Inputs: newsSentiment, dayChange
Sentiment 58/100 + price -1.6% are both mid-range.
Inputs: unusualVolume, dayChange
Volume read 26/100 with price drift -1.6% — no clear footprint.
Inputs: volatilityRisk, momentum
Vol regime 56/100 is mid-range — no edge.
Inputs: pctOfRange, trendVelocity
Mid-range positioning — no edge from range alone.
Inputs: newsSentiment, weekChange
Sentiment 58/100 vs week change 2.7% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price -15.6% under 50d SMA with no momentum reclaim — downtrend intact.
Inputs: momentum, trendVelocity
Composite oscillator at 17 — washed-out zone, mean-reversion candidate.
Inputs: momentum, dayChange, vsSma50
Momentum 12/100 with negative tape and price under the 50d SMA — downside continuation.
Inputs: newsSentiment, weekChange
News 58/100 and weekly change 2.7% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 26/100 is quiet and trend velocity is weak — move lacks sponsorship.
Inputs: volatilityRisk, pctOfRange, momentum
Volatility 56/100 does not give a clean compression read.
Inputs: pctOfRange, dayChange, weekChange
Range position 32% is too middle-of-the-road to matter.
Inputs: newsSentiment, momentum, weekChange
Sentiment 58/100 and momentum 12/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
Price is still under the 50d SMA and the trend has not reclaimed control.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 17 with weekly stabilization is a rebound setup.
Why the ensemble agrees
- Momentum 12/100 with trend velocity 22/100 — trend is rolling over.
- Momentum 12/100 with negative tape and price under the 50d SMA — downside continuation.
- Price -15.6% under 50d SMA with no momentum reclaim — downtrend intact.
Counter-trees
- Composite oscillator at 17 — washed-out zone, mean-reversion candidate.
- Oscillator at 17 with weekly stabilization is a rebound setup.
Bull Case
- Composite oscillator at 17 — washed-out zone, mean-reversion candidate.
- Oscillator at 17 with weekly stabilization is a rebound setup.
Bear Case
- Momentum 12/100 with trend velocity 22/100 — trend is rolling over.
- Price -15.6% under 50d SMA with no momentum reclaim — downtrend intact.
- Momentum 12/100 with negative tape and price under the 50d SMA — downside continuation.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
Yahoo Finance60
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
9/4/2025, 8:06:00 AM
Yahoo Finance58
Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
10/20/2026, 7:14:00 AM
Stocktwits63
IMVT, ROIV stocks slide as Argenx Sjögren’s trial failure hits drug class
10/8/2026, 10:33:32 AM
Nasdaq56
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2/11/2025, 4:01:00 PM
MSN54
IMVT stock on track for 4-month low after phase 3 setback in thyroid eye disease trials
4/2/2026, 4:27:00 AM
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Market cap
- $6.03B
- 52-week range
- $45.42/$21.43
- Volume
- 1,165,454
- Avg volume
- 1,375,711
- Analyst 1-yr target
- $46.00
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Insider trades
0 buys · 1 sells by IMVT insiders (SEC Form 4 filings)
- SELL Stout Jay S Chief Technology Officer · 2026-10-23$75K
Earnings Intelligence
Next
Nov 9, 2026
Estimate
$-0.73
Actual
$-0.75
- • Last report Aug 6, 2026 (Jun 2026): EPS $-0.75 vs $-0.66 expected, -13.64% surprise.
- • Beat estimates in 1 of the last 4 quarters.
- • Next report expected Nov 9, 2026, consensus EPS $-0.73 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • Markets can move against any signal regardless of the score.
- • Confirm liquidity, spreads, and your own thesis before acting.
IMVT questions
What is the MarketPicks AI signal for Immunovant, Inc. stock (IMVT)?
As of Nov 1, 10:55 PM ET, the ensemble reads bearish on IMVT — bearish — 5 of 16 bots down, with 2 bull, 5 bear and 9 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest IMVT price on MarketPicks?
IMVT was $29.17 on the latest quote (Nov 1, 10:55 PM ET), -1.59% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for IMVT mean?
Scores run from 0 to 100, with 50 neutral. IMVT shows momentum 12/100, trend velocity 22/100 and volatility risk 56/100, with news sentiment at 58/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.